<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01421940</url>
  </required_header>
  <id_info>
    <org_study_id>KNUHCRC002</org_study_id>
    <nct_id>NCT01421940</nct_id>
  </id_info>
  <brief_title>The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyungpook National University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sexual dysfunctions are well-recognized complications after rectal cancer surgery. Damage to
      the pelvic plexus and pelvic splanchnic nerves results in ejaculatory dysfunction. The
      purpose of this study is to evaluate the efficacy of Udenafil(Zydena®, Dong-A Pharmaceutical
      co., Ltd, Seoul, Korea) in penile rehabilitation for patients who undertake total mesorectal
      excision.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in International Index of Erectile Function (5-item Version) at 12 and 24 week</measure>
    <time_frame>Baseline, 12weeks, 24 weeks</time_frame>
    <description>IIEF-5 questionnaire is used to assess male erectile function
IIEF-5 (5-item Version of the International Index of Erectile Function)is obtained by combining the scores of the responses to 5 questions. Each question is scored from 0-5 (1 questions is scored from 1-5) for IIEF-5 range of 1-25 points; lower numerical scores from the IIEF-5 questionnaire represnt greater severitt of erectile dysfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SEP Q2,Q3 and GEQ</measure>
    <time_frame>baseline, 12weeks, and 24 weeks</time_frame>
    <description>SEP Q2 (Sexual encounter profile Q2) and SEP Q3 (Sexual encounter profile Q3) are used to assess erectile function
The efficaty of medication is followed by GEQ (Global efficacy question).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events during 24 weeks of the study</measure>
    <time_frame>Baseline through 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individuals who take placebo after total mesorectal excision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Udenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals who take udenafil after total mesorectal excision</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo drug</intervention_name>
    <description>After total mesorectal excision for rectal cancer, patients take placebo drug five time per week for 12 weeks.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Udenafil</intervention_name>
    <description>After total mesorectal excision, patients take 50mg udenafil five times per week for 12 weeks.</description>
    <arm_group_label>Udenafil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age : 20-65

          -  Rectal cancer within 15cm from anal verge

          -  Patients with more than 5 points decreased IIEF-5 after operation

          -  Patients with sexual activity

        Exclusion Criteria:

          -  Preoperative IIEF-5 : ≤14

          -  Recent MI, CVA, nitrate medication

          -  Severe cardiovascular disease, psychiatric disease

          -  Severe hepatic dysfunction (GOT, GPT ≥100IU/L)

          -  Renal dysfunction (Cr ≥2mg/dl)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyungpook National University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>702-210</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2011</study_first_submitted>
  <study_first_submitted_qc>August 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2011</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University</investigator_affiliation>
    <investigator_full_name>Gyu-Seog Choi</investigator_full_name>
    <investigator_title>Colorectal Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Udenafil</keyword>
  <keyword>rectal cancer</keyword>
  <keyword>penile rehabilitation</keyword>
  <keyword>total mesorectal excision</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Udenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

